TLTFF (Theralase Technologies) Debt-to-Equity : 0.14 (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Theralase Technologies Debt-to-Equity?

Theralase Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.07 Mil. Theralase Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.14 Mil. Theralase Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $1.45 Mil. Theralase Technologies's debt to equity for the quarter that ended in Dec. 2024 was 0.14.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Theralase Technologies's Debt-to-Equity or its related term are showing as below:

TLTFF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.08 Max: 0.2
Current: 0.14

During the past 13 years, the highest Debt-to-Equity Ratio of Theralase Technologies was 0.20. The lowest was 0.01. And the median was 0.08.

TLTFF's Debt-to-Equity is ranked better than
62.37% of 691 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs TLTFF: 0.14

Theralase Technologies Debt-to-Equity Historical Data

The historical data trend for Theralase Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies Debt-to-Equity Chart

Theralase Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.15

0.20

0.14

Theralase Technologies Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															0.20	0.19	0.21	0.15	0.14

Competitive Comparison of Theralase Technologies's Debt-to-Equity

For the Medical Devices subindustry, Theralase Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralase Technologies's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Theralase Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Theralase Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.07	+	0.136)	/	1.451
	=	0.14

Theralase Technologies's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.07	+	0.136)	/	1.451
	=	0.14

Theralase Technologies (OTCPK:TLTFF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Theralase Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (OTCPK:TLTFF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

TTX:Germany TTX:Germany TLT:Canada

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.